What is the official website of Dengue Academy ?

The official website of Dengue Academy is http://www.dengueacademy.com.

What is Dengue Academy's cybersecurity risk score?

Dengue Academy has an AI-generated cybersecurity risk score of 755 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Dengue Academy experienced?

According to Rankiteo, Dengue Academy currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Dengue Academy been affected by any supply chain cyber incidents ?

According to Rankiteo, Dengue Academy has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Dengue Academy have SOC 2 Type 1 certification ?

According to Rankiteo, Dengue Academy is not certified under SOC 2 Type 1.

Does Dengue Academy have SOC 2 Type 2 certification ?

According to Rankiteo, Dengue Academy does not hold a SOC 2 Type 2 certification.

Does Dengue Academy comply with GDPR ?

According to Rankiteo, Dengue Academy is not listed as GDPR compliant.

Does Dengue Academy have PCI DSS certification ?

According to Rankiteo, Dengue Academy does not currently maintain PCI DSS compliance.

Does Dengue Academy comply with HIPAA ?

According to Rankiteo, Dengue Academy is not compliant with HIPAA regulations.

Does Dengue Academy have ISO 27001 certification ?

According to Rankiteo,Dengue Academy is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Dengue Academy operate in ?

Dengue Academy operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Dengue Academy have ?

Dengue Academy employs approximately None employees people worldwide.

Does Dengue Academy own any subsidiaries ?

Dengue Academy presently has no subsidiaries across any sectors.

How many LinkedIn followers does Dengue Academy have ?

Dengue Academy's official LinkedIn profile has approximately 5,267 followers.

What is the NAICS classification code for Dengue Academy ?

Dengue Academy is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Dengue Academy have a Crunchbase profile ?

No, Dengue Academy does not have a profile on Crunchbase.

Does Dengue Academy have a LinkedIn profile ?

Yes, Dengue Academy maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/dengue-academy.

How many cybersecurity incidents has Dengue Academy experienced ?

As of September 19, 2026, Rankiteo reports that Dengue Academy has experienced 1 cybersecurity incidents.

How many peer or competitor companies does Dengue Academy have ?

Dengue Academy has an estimated 5,767 peer or competitor companies worldwide.

What types of cybersecurity incidents has Dengue Academy faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Dengue Academy

Boost Score +25 with badge (5 left)

755

/1000

Fair

780

/1000

Fair

Dengue Academy Vendor Cyber Rating & Cyber Score

dengueacademy.com

Add Your Compliance Badge

A comprehensive website for healthcare professionals (HCPs), covering topics such as the epidemiology, diagnosis, burden, and control of dengue. HCPs will have access to online events, continuing medical education (CME), research summaries, and more. Read our community guidelines: https://www.takeda.com/newsroom/social-media/

Dengue Academy

Dengue Academy CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Dengue Academy

Breach

1/2024

BIO201072825

Loading…

A.I.

Dengue Academy Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Dengue Academy

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Dengue Academy in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Dengue Academy in 2026.

Incident Types Dengue Academy vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Dengue Academy in 2026.

Incident History - Dengue Academy (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Dengue Academy Subsidiaries

Dengue Academy

Pharmaceutical Manufacturing

Website: http://www.dengueacademy.com

Company Size: None employees

TakedaPharmaceutical Manufacturing

Takeda OncologyPharmaceutical Manufacturing

ARIAD Pharmaceuticals, Inc.Pharmaceutical Manufacturing

Takeda Canada Inc.Pharmaceutical Manufacturing

BioLife Plasma ServicesPharmaceutical Manufacturing

TAKEDA IBDpointServizi benessere e fitness

Loading…

Dengue Academy Similar Companies

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Fresenius Kabi

fresenius-kabi.com

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Medical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Loading…

NEWS

Dengue Academy CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

July 25, 2025 07:00 AM

Mind The Bite: Mosquitoes Can Wreck Brain, Not Just Cause Dengue, Malaria

Nagpur: Next time a mosquito bites you, there's more to worry about than just malaria or dengue. Experts say that mosquitoes are spreading...

Read Article

March 06, 2025 08:09 AM

TCS Partners with the Danish Academy of Technical Sciences to Combat Dengue Through Technology and Citizen Engagement

TCS will provide data-driven technology support to the program through its pro bono initiative, TCS TECH4HOPE.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-93740

SUMMARY

A vulnerability was identified in Totolink A3002MU Hh-B20211125.1046. Affected is the function formWlEncrypt of the file /boafrm/formWlEncrypt. The manipulation of the argument submit-url leads to buffer overflow. It is possible to initiate the attack remotely. The exploit is publicly available and might be used.

Published

Date2026-09-18

Updated

Date2026-09-18

RISK INFORMATION (Score: 10)

cvss2

Base Score: 10.0

Complexity: LOW

AV:N/AC:L/Au:N/C:C/I:C/A:C

cvss3

Base Score: 10.0

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

3.9

REFERENCES

CVE-2026-93739

SUMMARY

A vulnerability was determined in Totolink A3002MU Hh-B20211125.1046. This impacts the function formWlAc of the file /boafrm/formWlAc. Executing a manipulation of the argument submit-url can lead to buffer overflow. The attack may be performed from remote. The exploit has been publicly disclosed and may be utilized.

Published

Date2026-09-18

Updated

Date2026-09-18

RISK INFORMATION (Score: 9.9)

cvss2

Base Score: 9.0

Complexity: LOW

AV:N/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 9.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 8.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

3.1

REFERENCES

CVE-2026-75885

SUMMARY

A flaw was found in the OpenShift console. Unauthenticated access to the `/api/devfile/` and `/api/devfile/samples/` endpoints allows a remote attacker to send crafted devfile payloads. This can lead to Server-Side Request Forgery (SSRF), where the console pod makes requests to internal services and reflects partial responses to the attacker. Additionally, by sending repeated large requests without a specified content length, an attacker can cause unbounded memory growth, leading to a Denial of Service (DoS).

Published

Date2026-09-18

Updated

Date2026-09-18

RISK INFORMATION (Score: 9.3)

cvss3

Base Score: 9.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:N/A:L

Impact Score

4.7

Exploitability

3.9

REFERENCES

CVE-2026-93894

SUMMARY

In Vinyl Cache before 9.0,2, workspace buffer overflow vulnerability was found in the .upper() and .lower() string type methods of VCL. This can be used as a remote denial of service (DoS) vector to make the child process segfault or assert, and then restart. Effectively exploiting this vulnerability requires prior knowledge about the VCL in use and the ability to craft a request that contains a string that is long enough to fill the remaining workspace at the call site while staying under the different request size limits (http_req_size, http_req_hdr_len, etc.).

Published

Date2026-09-18

Updated

Date2026-09-18

RISK INFORMATION (Score: )

cvss4

Base Score: 2.3

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:L/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:N/R:A/V:D/RE:L/U:Clear

Impact Score

Exploitability

REFERENCES

https://vinyl-cache.org/security/VSV00020.html

CVE-2026-93738

SUMMARY

A vulnerability was found in Totolink A3002MU Hh-B20211125.1046. This affects the function formSchedule of the file /boafrm/formSchedule. Performing a manipulation of the argument webpage results in buffer overflow. The attack is possible to be carried out remotely. The exploit has been made public and could be used.

Published

Date2026-09-18

Updated

Date2026-09-18

RISK INFORMATION (Score: 9.9)

cvss2

Base Score: 9.0

Complexity: LOW

AV:N/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 9.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 8.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

3.1

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Dengue Academy Vendor Cyber Rating & Cyber Score

Dengue Academy A.I CyberSecurity Scoring

Dengue Academy CyberSecurity News & History

Dengue Academy Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Dengue Academy

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Dengue Academy vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Dengue Academy (X = Date, Y = Severity)

Dengue Academy Subsidiaries

Dengue Academy

Dengue Academy Similar Companies

Takeda

MSD

Intas Pharmaceuticals

MACLEODS PHARMACEUTICALS LTD.

Fresenius Kabi

Teva Pharmaceuticals

Novo Nordisk

Sanofi

PT Kalbe Farma, Tbk

Dengue Academy CyberSecurity News

Mind The Bite: Mosquitoes Can Wreck Brain, Not Just Cause Dengue, Malaria

TCS Partners with the Danish Academy of Technical Sciences to Combat Dengue Through Technology and Citizen Engagement

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Dengue Academy CyberSecurity News & History

Dengue Academy Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Dengue Academy

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Dengue Academy vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Dengue Academy (X = Date, Y = Severity)

Dengue Academy Subsidiaries

Dengue Academy

Dengue Academy Similar Companies

Takeda

MSD

Intas Pharmaceuticals

MACLEODS PHARMACEUTICALS LTD.

Fresenius Kabi

Teva Pharmaceuticals

Novo Nordisk

Sanofi

PT Kalbe Farma, Tbk

Dengue Academy CyberSecurity News

Mind The Bite: Mosquitoes Can Wreck Brain, Not Just Cause Dengue, Malaria

TCS Partners with the Danish Academy of Technical Sciences to Combat Dengue Through Technology and Citizen Engagement

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo